Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases
03 Octubre 2024 - 7:30AM
NetworkNewsAudio –
Annovis Bio Inc. (NYSE:
ANVS) announces the availability of a broadcast titled,
“Transforming Alzheimer’s Treatment: Innovative Combinations to
Boost Cognition.”
To hear the AudioPressRelease, please visit: The
NetworkNewsAudio
To view the full editorial, please
visit: https://nnw.fm/ZIUid
Annovis Bio Inc. is at the forefront of the movement to develop
new safe and effective drugs for neurodegenerative diseases,
including AD. The company has long pursued the goal to improve the
health of nerve cells and, in the process, improve cognition in
neurodegenerative disorders. The company’s lead drug candidate,
buntanetap, has completed late-stage AD and PD clinical trials and
was shown to be efficacious in both indications.
Earlier this year, Annovis announced promising results from its
phase 2/3 clinical trial of buntanetap as an oral therapy for early
AD. The study involved 353 patients and assessed buntanetap’s
efficacy on top of standard of care medications as well as its
safety.
About Annovis Bio
Inc.
Annovis Bio, headquartered in Malvern, Pennsylvania, is
dedicated to addressing neurodegeneration in diseases such as
Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The
company’s innovative approach targets multiple neurotoxic proteins,
aiming to restore brain function and improve the quality of life
for patients.
For more information, about the company, please visit
www.AnnovisBio.com.
NOTE TO INVESTORS: The latest news and
updates relating to ANVS are available in the company’s newsroom
at https://ibn.fm/ANVS http://nnw.fm/ANVS
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications
platform with a focus on financial news and content distribution
for private and public companies and the investment community. It
is one of 60+ brands within the Dynamic Brand
Portfolio @ IBN that
delivers: (1) access to a vast network of
wire solutions via InvestorWire to efficiently and
effectively reach a myriad of target markets, demographics and
diverse industries; (2) article
and editorial syndication to 5,000+
outlets; (3) press release
enhancement to ensure maximum
impact; (4) social media
distribution via IBN to millions of social media
followers; and (5) a full array of
tailored corporate communications solutions. With broad reach
and a seasoned team of contributing journalists and writers, NNW is
uniquely positioned to best serve private and public companies that
want to reach a wide audience of investors, influencers, consumers,
journalists and the general public. By cutting through the overload
of information in today’s market, NNW brings its clients
unparalleled recognition and brand awareness. NNW is where breaking
news, insightful content and actionable information converge.
For more information, please
visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or republished:
https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWireNew York, NY
www.NetworkNewsWire.com 212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN
Annovis Bio (AMEX:ANVS)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Annovis Bio (AMEX:ANVS)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025